Low-speed centrifugation of retroviral vectors absorbed to a particulate substrate: A highly effective means of enhancing retroviral titre

Gene Therapy

Volumn 7, Issue 11, 2000, Pages 914-923

  Darling, D ^a,b   Hughes, C ^a   Galea Lauri, J ^a   Gaken J ^a   Trayner, I D ^a   Kuiper, M ^a,c   Farzaneh, F ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

Centrifugation; Concentration; Fibronectin; Gene therapy; Retrovirus; Staphylococcus aureus

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CENTRIFUGATION; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; STAPHYLOCOCCUS AUREUS;

ANIMALIA; STAPHYLOCOCCUS AUREUS; UNIDENTIFIED RETROVIRUS;

EID: 0034043048     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301201     Document Type: Article

References (55)

1. Miller AD, Rosman GJ. Improved retro viral vectors for gene transfer and expression. Biotechniques 1989; 8: 980-990.
2. Riviere I, Brose K, Mulligan RC. Effects of retroviral design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995 92: 6733-6737.
3. Miller AD et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65: 2220-2224.
4. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for the production of high titre retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 1996; 93: 11400-11406.
5. Cosset F-L et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
6. Burns JC et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to a very high titre and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90: 8033-8037.
7. Kozak SL, Kabat D. Ping-pong amplification of a retroviral vector achieves high-level gene expression: human growth hormone production. J Virol 1990; 64: 3500-3508.
8. Parente MK, Wolfe JH. Production of increased titer retrovirus vectors from stable producer cell lines by superinfection and concentration. Gene Therapy 1996; 3: 756-760.
9. Kotani H et al. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994; 5: 19-28.
10. Bunnell BA et al. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci USA 1995; 92: 7739-7743.
11. Olsen JC, Sechelski J. Use of sodium butyrate to enhance production of retroviral vectors expressing CTFR cDNA. Hum Gene Ther 1995; 6: 1195-1202.
12. Manning JS, Hackett AJ, Darby NB Jr. Effect of polycations on sensitivity of balb/3T3 cells to murine leukaemia and sarcoma virus infectivity. Appl Microbiol 1971; 22: 1162-1163.
13. Toyoshima K, Vogt PK. Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions. Virology 1969; 38: 414-426.
14. Porter CD et al. Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo. J Virol 1998; 72: 4832-4840.
15. Chuck AS, Clarke MF, Palson BO. Retroviral infection is limited by brownian motion. Hum Gene Ther 1996; 7: 1527-1534.
16. Hanenberg H et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nature Med 1996; 2: 876-882.
17. Paul RW et al. Increased viral titer through concentration of viral harvests from retroviral packaging lines. Hum Gene Ther 1993; 4: 609-615.
18. Miller DL, Meikle PJ, Anson DS. A rapid and efficient method for concentration of small volumes of retroviral supernatant. Nucleic Acids Res 1996; 24: 1576-1577.
19. Chu T-HT, Dornburg R. Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. J Virol 1997; 71: 720-725.
20. Olsen JC, Johnson LG, Yankaskas JR. Methods for the use of retroviral vectors for transfer of the CTFR gene to airway epithelium. In: Robbins P (ed). Gene Therapy Protocols. Humana Press: New Jersey, 1997, pp 153-168.
21. Morling FJ, Russell SJ. Enhanced transduction efficiency of retroviral vectors coprecipitated with calcium phosphate. Gene Therapy 1995; 2: 504-508.
22. LeDoux JM, Morgan JR, Snow RG, Yarmush ML. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J Virol 1996; 70: 6468-6473.
23. Russell SJ. Making high titre retroviral producer cells. In: Collins MKL (ed). Methods in Molecular Biology: Vol 8 Practical Molecular Virology. Humana Press: New Jersey, 1991, pp 29-48.
24. Bowles NE et al. A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepotocyte transduction in vivo. Hum Gene Ther 1996; 7: 1735-1742.
25. Seppen J, Kimmel RJ, Osborne WRA. Serum-free production, concentration and purification of recombinant retroviruses. Biotechniques 1997; 23: 788-790.
26. McNeish IA et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Therapy 1998; 5: 1061-1069.
27. Liu M-L, Winther BL, Kay MA. Pseudotransduction of hepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein (VSV-G)-moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer. J Virol 1996; 70: 2497-2502.
28. Palson B, Andreadis S. The physio-chemical factors that govern retrovirus-mediated gene transfer. Exp Hematol 1997; 25: 94-102.
29. Morgan JR et al. Retrovirus infection - effect of time and target-cell number. J Virol 1995; 69: 6994-7000.
30. Gäken J et al. Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron (submitted).
31. Dardalhon V et al. Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T-lymphocytes. Hum Gene Ther 1999; 10: 5-14.
32. Signas C et al. Nucleotide sequence of the gene for fibronectin-binding protein from Staphylococcus aureus: use of this peptide sequence in the synthesis of biologically active peptides. Proc Natl Acad Sci USA 1989; 86: 699-703.
33. Jonsson K et al. Two different genes encode fibronectin binding proteins in Staphylococcus aureus: the complete nucleotide sequence and characterization of the second gene. Eur J Biochem 1991; 202: 1041-1048.
34. Shantz EM. PANSORBIN, Staphylococcus aureus cells: a review and bibliography of the immunological applications of fixed protein A-bearing Staphylococcus aureus cells. Calbiochem, 1994.
35. Freeman GT et al. B7, a new member of the IG superfamily with unique expression on activated and neoplastic B-cells. J Immunol 1989; 143: 2714-2722.
36. Spear GT et al. Host cell-derived complement proteins CD55 and CD59 are incorporated into the virions of 2 unrelated enveloped viruses - human T-cell leukemia/lymphoma virus type-1 (HTLV-1) and human cytomegalovirus (HCMV). J Immunol 1995; 155: 4376-4381.
37. Balliet JW, Bates P. Efficient infection mediated by viral receptors incorporated into retroviral particles. J Virol 1998; 72: 671-676.
38. Izumi M et al. Blasticidin S-resistance gene (bsr): a novel selectable marker for mammalian cells. Exp Cell Res 1991; 197: 229-233.
39. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
40. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
41. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988; 62: 1120-1124.
42. Kayman SC et al. The hypervariable domain of the murine leukaemia virus surface protein tolerates large insertions and deletions, enabling developement of a retroviral particle display system. J Virol 1999; 73: 1802-1808.
43. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent haematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci USA 1988; 85: 9312-9316.
44. Vercellotti GM et al. Extracellular matrix proteins (Fibronectin, Laminin, and Type IV Collagen) bind and aggregate bacteria. Am J Pathol 1985; 120: 13-21.
45. Jordan-Sciutto KL et al. Reduction in fibronectin expression and alteration in cell morphology are coincident in NIH3T3 cells expressing a mutant E2F1 transcription factor. Exp Cell Res 1997; 236: 527-536.
46. Dean DC, Newby RF, Bourgeois S. Regulation of fibronectin biosynthesis by dexamethasone, transforming growth factor-beta, and cAMP in human cell-lines. J Cell Biol 1988; 106: 2159-2170.
47. Gerin PA et al. Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium. Hum Gene Ther 1999; 10: 1965-1974.
48. Touhami M, Bourge J-F, Legrand C. Increased adhesion of the promyelocyte leukaemia cell line, NB4, to fibronectin and thrombospondin upon all-trans-retinoic acid treatment. Br J Haematol 1999; 104: 706-714.
49. Bansal SC et al. Ex vivo removal of serum IgG in a patient with colon carcinoma. Some biochemical, immunological and histological observations. Cancer 1978; 42: 1-18.
50. Cowan FM. Staphylococcus Aureus protein A immunoadsorption: the rationale for systemic protein A immunotherapy. Toxicol Meth 1997; 7: 9-15.
51. Steele G, Ankerst J, Sjogren HO. Alteration of in vitro anti-tumour activity of tumour-bearer sera by adsorption with Staphylococcus aureus. Int J Cancer 1974; 14: 83-92.
52. Fennelly DW et al. A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer. Cancer 1995; 75: 2099-2102.
53. Messerschmidt GL et al. Protein A immunotherapy in the treatment of cancer: an update. Semin Hematol 1989; 26 (Suppl. 1): 19-24.
54. Engelman RW, Good RA, Day NK. Clearance of retroviremia and regression of malignancy in cats with leukemia-lymphoma during treatment with staphylococcal protein A. Cancer Detect Prev 1987; 10: 435-444.
55. Snyder HW, Reed DE, Jones FR. Remission of FeLV-associated lymphosarcoma and persistent viral infection after extracorporeal immunoadsorption of plasma using staphylococcal protein A columns: details of immune response. Semin Hematol 1989; 26 (Suppl. 1): 25-30.